Explore

Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback
Trendline Trendline
Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges
Trendline Trendline
Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development
Trendline Trendline
Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases
Trendline Trendline
Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies
Trendline Trendline
Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI

Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI

Tempus and Bristol Myers Squibb Collaborate to Enhance Clinical Trials with AI
Trendline Trendline
PureTech to Present Deupirfenidone Program at American Thoracic Society Conference, Aiming to Transform IPF Treatment

PureTech to Present Deupirfenidone Program at American Thoracic Society Conference, Aiming to Transform IPF Treatment

PureTech to Present Deupirfenidone Program at American Thoracic Society Conference, Aiming to Transform IPF Treatment
Trendline Trendline
Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab

Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab

Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab
Trendline Trendline
Immunome Advances Cancer Therapy Pipeline with New Drug Application and Clinical Trials

Immunome Advances Cancer Therapy Pipeline with New Drug Application and Clinical Trials

Immunome Advances Cancer Therapy Pipeline with New Drug Application and Clinical Trials
Trendline Trendline
Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases
Trendline Trendline
IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development